California State Teachers Retirement System Sells 2,494 Shares of Krystal Biotech, Inc. $KRYS

California State Teachers Retirement System lessened its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 9.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,692 shares of the company's stock after selling 2,494 shares during the quarter. California State Teachers Retirement System owned about 0.08% of Krystal Biotech worth $8,805,606 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in Krystal Biotech during the second quarter worth about $1,554,113,000. Avoro Capital Advisors LLC grew its position in Krystal Biotech by 4.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company's stock worth $712,226,000 after acquiring an additional 111,111 shares in the last quarter. William Blair Investment Management LLC bought a new stake in Krystal Biotech in the second quarter valued at $211,909,000. Jupiter Topco LLC bought a new position in Krystal Biotech in the second quarter valued at approximately $95,387,000. Finally, Bank of America Corp DE bought a new stake in shares of Krystal Biotech in the second quarter worth $95,308,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Trading Down 0.9%

Shares of NASDAQ:KRYS traded down $3.16 during trading on Tuesday, hitting $336.87. 93,059 shares of the company were exchanged, compared to its average volume of 331,171. Krystal Biotech, Inc. has a fifty-two week low of $151.88 and a fifty-two week high of $382.54. The stock has a market cap of $9.97 billion, a price-to-earnings ratio of 42.28 and a beta of 0.54. The firm has a fifty day moving average price of $346.69 and a two-hundred day moving average price of $310.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating analysts' consensus estimates of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The business had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. As a group, research analysts predict that Krystal Biotech, Inc. will post 7.48 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on KRYS. Jefferies Financial Group reaffirmed a "buy" rating and issued a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. Chardan Capital raised Krystal Biotech to a "strong-buy" rating in a report on Monday, August 3rd. Weiss Ratings cut shares of Krystal Biotech from a "buy (b)" rating to a "buy (b-)" rating in a research report on Tuesday, August 18th. HC Wainwright lifted their price target on Krystal Biotech from $310.00 to $361.00 and gave the stock a "buy" rating in a research note on Tuesday, June 16th. Finally, Wall Street Zen downgraded shares of Krystal Biotech from a "buy" rating to a "hold" rating in a research report on Saturday, June 20th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, Krystal Biotech currently has a consensus rating of "Moderate Buy" and a consensus target price of $365.40.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the sale, the insider directly owned 1,302,145 shares in the company, valued at $467,886,741.40. This represents a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares of the company's stock, valued at $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 51,000 shares of company stock worth $17,558,270. 13.10% of the stock is owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas.

Krystal Biotech's lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.